Diagnosis, Natural History, Management and tumor biology of Gastrinomas

$392,059ZIAFY2009DKNIH

National Institute Of Diabetes And Digestive And Kidney Diseases

Investigators

Linked publications & trials

Paper 39000391 Paper 36900170 Paper 35267558 Paper 35233848 Paper 34539578 Paper 34529832 Paper 34515664 Paper 34515662 Paper 33385499 Paper 33131345 Paper 32971521 Paper 32964398 Paper 30282083 Paper 30178021 Paper 30153686 Paper 30098717 Paper 29973077 Paper 29757017 Paper 29517561 Paper 29365025 Paper 29326808 Paper 29164297 Paper 29120923 Paper 28426491 Paper 28391265 Paper 28334992 Paper 28230660 Paper 28099257 Paper 27875420 Paper 27635672 Paper 27582247 Paper 27539256 Paper 26834963 Paper 26742109 Paper 26542588 Paper 26378090 Paper 26363542 Paper 26291955 Paper 25220535 Paper 24636662 Paper 24499825 Paper 24100728 Paper 23645327 Paper 23591432 Paper 23582916 Paper 23363383 Paper 23112541 Paper 23093487 Paper 22987171 Paper 22886480 Paper 22868363 Paper 22586144 Paper 22504376 Paper 22350475 Paper 22261919 Paper 21860682 Paper 21690450 Paper 21556022 Paper 21306243 Paper 21160582 Paper 20882439 Paper 20725788 Paper 20669078 Paper 20664473 Paper 20664472 Paper 20567543 Paper 20118772 Paper 20058030 Paper 19903418 Paper 18798544 Paper 18780869 Paper 18270260 Paper 17312377 Paper 17312376 Paper 17108779 Paper 17108778 Paper 16926567 Paper 16622982 Paper 16451771 Paper 16433886 Paper 16253893 Paper 16249283 Paper 15867218 Paper 15853832 Paper 15802099 Paper 15657586 Paper 15527675 Paper 15082965 Paper 15042671 Paper 12097278 Paper 11144036 Paper 11037994 Paper 10909042 Paper 10888424

Abstract

Gastrinomas are the most common symptomatic, malignant PET in patients with or without MEN1 and sufficient numbers of these patients have been entered into our protocols to allow systematic assessment. Studies are now underway, evaluating the natural history of these tumors including the presentation and initial diagnosis and definition of factors determining prognosis. Our studies have identified a cohort of 25% of patients in whom the gastrinomas have aggressive growth and 25% who have multiple endocrine neoplasia type 1 (MEN1). During this year a prospective study of surgical treatment of hyperparathyroidism in MEN1 patients was completed showing that they have more severe disease than occurs in patients with MEN1 without gastrinomas;a prosepctive study of the occurrence of gastric carcinoids in MEN1/ZES patients was complete establishing the incidence of these tumors in these patients and recommending appropriate followup and prognostic factors for their presence, and a number of consensus conferences and position papers on treatment of various disease aspects were published.

View original record on NIH RePORTER →